Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF

Kate Sumpter; Catherine Harper‐Wynne; David Cunningham; Sheela Rao; Niall C. Tebbutt; A. Norman; Chris Ward; Timothy Iveson; M. Nicolson; Tamas Hickish; Mark Hill; J. Oates

doi:10.1038/sj.bjc.6602572

Keywords

CapecitabineMedicineInterim analysisOxaliplatinEpirubicinInternal medicineMucositisFluorouracilCancerGastroenterologyFebrile neutropeniaChemotherapySurgeryNeutropeniaClinical trialBreast cancerColorectal cancer

Affiliated Institutions

Related Publications

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran , Nils Homann , Claudia Pauligk +54 more

Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-ba...

2019 The Lancet 2355 citations

Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer

Paul J. Ross , M. Nicolson , David Cunningham +9 more

PURPOSE: We report the results of a prospectively randomized study that compared the combination of epirubicin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU)...

2002 Journal of Clinical Oncology 481 citations

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy , Jean-François Bosset , Pierre-Luc Etienne +54 more

2021 The Lancet Oncology 1089 citations

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

Justin S. Waters , A. Norman , David Cunningham +12 more

We report the final results of a prospectively randomized study that compared the combination of epirubicin, cisplatin and protracted venous infusion fluorouracil (5-FU) (ECF re...

1999 British Journal of Cancer 278 citations

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

Andrew Webb , David Cunningham , J.H. Scarffe +16 more

PURPOSE We report the results of a prospectively randomized study that compared the combination of epirubicin, cisplatin, and protracted venous infusion fluorouracil (5-FU) (ECF...

1997 Journal of Clinical Oncology 871 citations

Publication Info

Year: 2005
Type: article
Volume: 92
Issue: 11
Pages: 1976-1983
Citations: 143
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

143

OpenAlex

Cite This

APA Style

                            
                                
                                    Kate Sumpter, 
                                
                                    Catherine Harper‐Wynne, 
                                
                                    David Cunningham
                                
                                et al.
                            
                            (2005). 
                            Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. 
                            British Journal of Cancer
                            , 92
                            (11)
                            , 1976-1983.
                            https://doi.org/10.1038/sj.bjc.6602572
                        

Identifiers

DOI: 10.1038/sj.bjc.6602572